Shuichi Izumoto1, Masaharu Miyauchi2, Takayuki Tasaki2, Takeshi Okuda2, Nobuhiro Nakagawa2, Naoki Nakano2, Amami Kato2, Mitsugu Fujita3. 1. Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan sizumoto@med.kindai.ac.jp mfujita47@gmail.com. 2. Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 3. Department of Microbiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan sizumoto@med.kindai.ac.jp mfujita47@gmail.com.
Abstract
BACKGROUND/AIM: Excessive extracellular glutamate activates AMPA-type glutamate receptors (AMPA receptors) and induces seizures. Antagonistic activation of AMPA receptors inhibits epilepsy and glioma growth in in vitro and in vivo studies. This study was conducted to evaluate the clinical impacts of perampanel (PER), a novel AMPA receptor antagonist, on seizures and tumor progression in glioma patients with uncontrollable epilepsy. PATIENTS AND METHODS: Twelve glioma patients with uncontrollable epilepsy were treated with PER. Seizure response, PER concentration, and tumor volume were assessed. RESULTS: Obvious seizure control was observed in 10 analyzed patients (100%) and 6 patients (60%) became seizure-free. Median plasma concentrations of PER were 296 ng/ml in those with 4 mg/day PER treatment and 518 ng/ml in those with 8 mg/day PER treatment. High-intensity lesions in fluid-attenuated inversion recovery of magnetic resonance imaging (MRI) were volumetrically assessed to analyze tumor size. Volume reduction was detected within 6 months in correlation with increased plasma levels of PER. CONCLUSION: PER treatment was effective in uncontrollable epilepsy with gliomas. MRI images showed the inhibition of tumor growth. Copyright
BACKGROUND/AIM: Excessive extracellular glutamate activates AMPA-type glutamate receptors (AMPA receptors) and induces seizures. Antagonistic activation of AMPA receptors inhibits epilepsy and glioma growth in in vitro and in vivo studies. This study was conducted to evaluate the clinical impacts of perampanel (PER), a novel AMPA receptor antagonist, on seizures and tumor progression in gliomapatients with uncontrollable epilepsy. PATIENTS AND METHODS: Twelve gliomapatients with uncontrollable epilepsy were treated with PER. Seizure response, PER concentration, and tumor volume were assessed. RESULTS: Obvious seizure control was observed in 10 analyzed patients (100%) and 6 patients (60%) became seizure-free. Median plasma concentrations of PER were 296 ng/ml in those with 4 mg/day PER treatment and 518 ng/ml in those with 8 mg/day PER treatment. High-intensity lesions in fluid-attenuated inversion recovery of magnetic resonance imaging (MRI) were volumetrically assessed to analyze tumor size. Volume reduction was detected within 6 months in correlation with increased plasma levels of PER. CONCLUSION: PER treatment was effective in uncontrollable epilepsy with gliomas. MRI images showed the inhibition of tumor growth. Copyright
Authors: Falko Lange; Konrad Weßlau; Katrin Porath; Julia Hörnschemeyer; Carina Bergner; Bernd Joachim Krause; Christina Susanne Mullins; Michael Linnebacher; Rüdiger Köhling; Timo Kirschstein Journal: PLoS One Date: 2019-02-04 Impact factor: 3.240
Authors: Marco Zoccarato; Lucia Nardetto; Anna Maria Basile; Bruno Giometto; Vittorina Zagonel; Giuseppe Lombardi Journal: Front Oncol Date: 2021-03-22 Impact factor: 6.244